Helus Pharma Reports Psychedelic Drug Efficacy in Depression Trial Alongside Safety Concerns
A Phase 3 clinical trial indicates a psychedelic drug candidate significantly reduces major depression symptoms, though multiple serious adverse events prompt safety inquiries.
🥗NutritionPhoto: statnews.com
Key points
- Helus Pharma announced Phase 3 trial results for a psychedelic depression treatment.
- Patients on the drug combined with standard antidepressants saw greater MADRS score reductions.
- Serious adverse events raised questions regarding the treatment's safety profile.
A recent Phase 3 clinical trial evaluating a psychedelic drug candidate from Helus Pharma demonstrated significant symptom reduction in patients suffering from major depression, according to an announcement made by the company on Monday. Participants receiving the experimental therapy alongside standard antidepressants achieved a notable decrease in depressive symptoms, as measured by the MADRS rating scale, compared to those receiving a placebo.
Specifically, at the six-week mark, patients taking the active drug recorded an average reduction of 19.5 points on the scale, whereas the placebo cohort observed an 11.9-point drop. This therapeutic effect remained largely consistent through twelve weeks, with the treatment group maintaining a 16.9-point reduction against a 9.9-point decrease for the placebo group. The reported differences between both cohorts achieved statistical significance.
Despite the encouraging efficacy data, the study revealed a series of serious adverse events that have introduced questions regarding the overall safety profile of the intervention. Because the available findings are currently limited to company announcements without full peer-reviewed data, medical professionals emphasize the need for caution. Patients should always consult a qualified healthcare provider before making any personal medical decisions.
What to know
- Treatment Context: The psychedelic compound was tested as an add-on therapy alongside standard antidepressant medications.
- Trial Timeline: Results were measured at six and twelve weeks, showing sustained differences over the placebo group.
- Safety Questions: Serious adverse events reported during the study highlight potential risks that require further evaluation.
Source statnews.com — statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial… ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…